Page 94 - 2021_12-Haematologica-web

E. W. Petersdorf et al.
References
1. Gluckman E, Broxmeyer HA, Auerbach AD, et al. Hematopoietic reconstitution in a patient with Fancon’s anemia by means of umbilical-cord blood from an HLA-iden- tical sibling. N Engl J Med. 1989; 321(17):1174-1178.
2. Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord blood as a poten- tial source of transplantable hematopoietic stem/progenitor cells. Proc Natl Acad Sci U S A. 1989;86(10):3828-3832.
3. Wagner JE, Broxmeyer HE, Byrd RL, et al. Transplantation of umbilical cord blood after myeloablative therapy: analysis of engraftment. Blood. 1992;79(7):1874-1881.
4. Gluckman E, Rocha V, Boyer-Chammard A, et al. Outcome of cord-blood transplan- tation from related and unrelated donors. Eurocord Transplant Group and the European Blood and Marrow Transplantation Group. N Engl J Med. 1997;337(6):373-381.
5. Rubinstein P, Carrier C, Scaradavou A, et al. Outcomes among 562 recipients of placen- tal-blood transplants from unrelated donors. N Engl J Med. 1998;339(22):1565- 1577.
6. Rocha V, Wagner JE, Sobocinski KA, et al. Graft-versus-host disease in children who have received a cord-blood or bone mar- row transplant from an HLA-identical sib- ling. Eurocord and International Bone Marrow Transplant Registry Working Committee on Alternative Donor and Stem Cell Sources. N Engl J Med. 2000; 342(25):1846-1854.
7. Eapen M, Rubinstein P, Zhang MJ, et al. Outcomes of transplantation of unrelated donor umbilical cord blood and bone mar- row in children with acute leukemia: a comparison study. Lancet. 2007; 369(9577):1947-1954.
8. Willemze R, Rodrigues CA, Labopin M, et al. KIR-ligand incompatibility in the graft- versus-host direction improves outcomes after umbilical cord blood transplantation for acute leukemia. Leukemia. 2009; 23(3):492-500.
9. Brunstein CG, Wagner JE, Weisdorf DK, et al. Negative effect of KIR alloreactivity in recipients of umbilical cord blood trans- plant depends on transplantation condi- tioning intensity. Blood. 2009;113(22):5628- 5634.
10. Tanaka J, Morishima Y, Takahashi Y, et al. Effects of KIR ligand incompatibility on clinical outcomes of umbilical cord blood transplantation without ATG for acute leukemia in complete remission. Blood Cancer J. 2013;3(11):e164.
11. Barker JN, Boughan K, Dahi PB, et al. Racial disparities in access to HLA-matched unre- lated donor transplants: a prospective 1312- patient analysis. Blood Adv. 2019;3(7):939- 944.
12. Milano F, Gooley T, Wood B, et al. Cord- blood transplantation in patients with min- imal residual disease. N Engl J Med. 2016;375(10):944-953.
13. Small TN, Papadopoulos EB, Boulad F, et al. Comparison of immune reconstitution
after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions. Blood. 1999;93(2):467-480.
14. Thomson BG, Robertson KA, Gowan D, et al. Analysis of engraftment graft-versus- host disease, and immune recovery follow- ing unrelated donor cord blood transplanta- tion. Blood. 2000;96(8):2703-2711.
15. Ruggeri A, Peffault de Latour R, Carmagnat M, et al. Outcomes, infections, and immune reconstitution after double cord blood transplantation in patients with high- risk hematological diseases. Transpl Infect Dis. 2011;13(5):456-465.
16. Jacobson CA, Turki AT, McDonough SM, et al. Immune reconstitution after double cord blood stem cell transplantation com- parison with unrelated peripheral blood stem cell transplantation. Biol Blood Marrow Transplant. 2012;18(4):565-574.
17. Garfall A, Kim HT, Sun L, et al. KIR ligand incompatibility is not associated with relapse reduction after double umbilical cord blood transplantation. Bone Marrow Transplant. 2013;48(7):1000-1002.
19. Sekine T, Marin D, Cao K, et al. Specific combinations of donor and recipient KIR- HLA genotypes predict for large differences in outcome after cord blood transplanta- tion. Blood. 2016;128(2):297-312.
19. Petersdorf E, Carrington M, O’hUigin C, et al. Role of HLA-B exon 1 in graft-versus- host disease after unrelated haemopoietic cell transplantation: a retrospective cohort study. Lancet Haematol. 2020;7(1):e50-e60.
20. Petersdorf EW, Stevenson P, Bengtsson M, et al. HLA-B leader and survivorship after HLA-mismatched unrelated donor trans- plantation. Blood. 2020;136(3):362-369.
21. Horowitz A, Djaoud Z, Nemat-Gorgani N, et al. Class I HLA haplotypes form two schools that educate NK cells in different ways. Sci Immunol. 2016;1(3):eaag1672.
22. Braud V, Jones EY, McMichael A. The human major histocompatibility complex class Ib molecule HLA-E binds signal sequence-derived peptides with primary anchor residues at positions 2 and 9. Eur J Immunol. 1997;27(5):1164-1169.
23. Merino AM, Song W, He D, et al. HLA-B signal peptide polymorphism influences the rate of HIV acquisition but not viral load. J Infect Dis. 2012;205(12):1797-1805.
24. Ramsuran V, Naranbhai V, Horowitz A, et al. Elevated HLA-A expression impairs HIV control through inhibition of NKG2A- expressing cells. Science. 2018; 359(6371):86-90. Erratum in: Science. August 2, 2019.
25. Eapen M, Klein JP, Sanz GF, et al. Effect of donor-recipient HLA matching at HLA A, B, C, and DRB1 on outcomes after umbili- cal-cord blood transplantation for leukaemia and myelodysplastic syndrome: a retrospective analysis. Lancet Oncol. 2011;12(13):1214-1221.
26. Eapen M, Wang T, Veys PA, et al. Allele- level HLA matching for umbilical cord blood transplantation for non-malignant diseases in children: a retrospective analy- sis. Lancet Haematol. 2017;4(7):e325-e333.
27. Rocha V, Gluckman E. Improving outcomes of cord blood transplantation: HLA match-
ing, cell dose and other graft- and trans- plantation –related factors. Br J Haematol. 2009;147(2):262-274.
28. HLA Informatics Group, The Anthony Nolan Research Institute. HLA nomencla- ture. http://hla.alleles.org/wmda/ index. html. Accessed March 6, 2020.
29. Ando T, Tachibana T, Tanaka M, et al. Impact of graft sources on immune recon- stitution and survival outcomes following allogeneic stem cell transplantation. Blood Adv. 2020;4(2):408-419.
30. Luevano M, Daryouzeh M, Alnabhan R, Querol S, Khakoo S, Madrigal A, Saudemont A. The unique profile of cord blood natural killer cells balances incom- plete maturation and effective killing func- tion upon activation. Hum Immunol. 2012; 73(3):248-257.
31.Bjorkstrom NK, Riese P, Heuts F, et al. Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK- cell differentiation uncoupled from NK-cell education. Blood. 2010;116(19):3853-3864.
32.Foley B, Cooley S, Verneris MR, et al. Cytomegalovirus reactivation after allo- geneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood. 2012;119(11):2665-2674.
33. Della Chiesa M, Falco M, Bertaina A, et al. Human cytomegalovirus infection pro- motes rapid maturation of NK cells expressing activating killer Ig-like receptor in patients transplanted with NKG2C-/- umbilical cord blood. J Immunol. 2014;192(4):1471-1479.
34.Guma M, Angulo A, Vilches C, Gomez- Lozano N, Malats N, Lopez-Botet M. Imprint of human cytomegalovirus infec- tion on the NK cell receptor repertoire. Blood. 2004;104(12):3664-3671.
35. Elmaagacli AH, Steckel NK, Koldehoff M, et al. Early human cytomegalovirus replica- tion after transplantation is associated with a decreased relapse risk: evidence for a putative virus-versus-leukemia effect in acute myeloid leukemia patients. Blood. 2011;118(5):1402-1412.
36. Green ML, Leisenring WM, Xie H, et al. CMV reactivation after allogeneic HCT and relapse risk: evidence for early protection in acute myeloid leukemia. Blood. 2013; 122(7):1316-1324.
37. Yokoyama H, Morishima Y, Fuji S, et al. Impact of HLA allele mismatch at HLA-A, - B, -C, and -DRB1 in single cord blood trans- plantation. Biol Blood Marrow Transplant. 2020;26(3):519-528.
38. Knorr DA, Bachanova V, Verneris MR, Miller JS. Clinical utility of natural killer cells in cancer therapy and transplantation. Semin Immunol. 2014;26(2):161-172.
39. Dahlberg CI, Sarhan D, Chrobok M, Duru AD, Alici E. Natural killer cell-based thera- pies targeting cancer: possible strategies to gain and sustain anti-tumor activity. Front Immunol. 2015;6:605.
40. Liu E, Marin D, Banerjee P, et al. Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors. N Engl J Med. 2020;382(6):545-553.
3114
haematologica | 2021; 106(12)